TCL Archive Abraxane-Gemcitabine Combination Extends Overall Survival in Phase III Trial January 31, 2014
TCL Archive Treatment Progress Increases Five Year Survival To 41%; Rates Compared For 10 Leading Cancers April 25, 1980